BRIEF-Detalimogene Demonstrates Improved Complete Response Rate Of 62% At 6 Months

Reuters

Nov 11, 2025

Nov 11 (Reuters) - enGene Holdings Inc ENGN.O:

DETALIMOGENE DEMONSTRATES IMPROVED COMPLETE RESPONSE RATE OF 62% AT 6 MONTHS
ENGENE HOLDINGS INC - 42% OF PATIENTS EXPERIENCED TREATMENT-RELATED ADVERSE EVENTS
ENGENE HOLDINGS INC - 1.6% OF PATIENTS HAD DOSE INTERRUPTIONS DUE TO ADVERSE EVENTS
ENGENE HOLDINGS INC: 0.8% OF PATIENTS EXPERIENCED DOSE DISCONTINUATIONS DUE TO TRAES

Source text: ID:nBw7kBBjga

Further company coverage: ENGN.O

((reuters.briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2582369605"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582369605\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582369605?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 20:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582369605","market":"nz","top_or_hot":-1,"title":"BRIEF-Detalimogene Demonstrates Improved Complete Response Rate Of 62% At 6 Months","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Detalimogene Demonstrates Improved Complete Response Rate Of 62% At 6 Months</title></head><body><p><span>Nov 11 (Reuters)</span><span> - </span>enGene Holdings Inc <span>ENGN.O</span>:</p><ul><li><p>DETALIMOGENE DEMONSTRATES IMPROVED COMPLETE RESPONSE RATE OF 62% AT 6 MONTHS</p></li><li><p><a href=\"https://laohu8.com/S/ENGN\">ENGENE HOLDINGS INC</a> - 42% OF PATIENTS EXPERIENCED TREATMENT-RELATED ADVERSE EVENTS</p></li><li><p>ENGENE HOLDINGS INC - 1.6% OF PATIENTS HAD DOSE INTERRUPTIONS DUE TO ADVERSE EVENTS</p></li><li><p>ENGENE HOLDINGS INC: 0.8% OF PATIENTS EXPERIENCED DOSE DISCONTINUATIONS DUE TO TRAES</p></li></ul><p>Source text: <span>ID:nBw7kBBjga</span></p><p>Further company coverage: <span>ENGN.O</span></p><p> ((reuters.briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Detalimogene Demonstrates Improved Complete Response Rate Of 62% At 6 Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Detalimogene Demonstrates Improved Complete Response Rate Of 62% At 6 Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-11 20:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Detalimogene Demonstrates Improved Complete Response Rate Of 62% At 6 Months</title></head><body><p><span>Nov 11 (Reuters)</span><span> - </span>enGene Holdings Inc <span>ENGN.O</span>:</p><ul><li><p>DETALIMOGENE DEMONSTRATES IMPROVED COMPLETE RESPONSE RATE OF 62% AT 6 MONTHS</p></li><li><p><a href=\"https://laohu8.com/S/ENGN\">ENGENE HOLDINGS INC</a> - 42% OF PATIENTS EXPERIENCED TREATMENT-RELATED ADVERSE EVENTS</p></li><li><p>ENGENE HOLDINGS INC - 1.6% OF PATIENTS HAD DOSE INTERRUPTIONS DUE TO ADVERSE EVENTS</p></li><li><p>ENGENE HOLDINGS INC: 0.8% OF PATIENTS EXPERIENCED DOSE DISCONTINUATIONS DUE TO TRAES</p></li></ul><p>Source text: <span>ID:nBw7kBBjga</span></p><p>Further company coverage: <span>ENGN.O</span></p><p> ((reuters.briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nTUA56H4S5:1","article_id":"2582369605","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582369605","pubTimestamp":1762865604,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Detalimogene Demonstrates Improved Complete Response Rate Of 62% At 6 MonthsNov 11 (Reuters) - enGene Holdings Inc ENGN.O:DETALIMOGENE DEMONSTRATES IMPROVED COMPLETE RESPONSE RATE OF 62% AT 6 MO","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ENGN":"ENGENE HOLDINGS INC"},"translate_title":"BRIEF-Detalimogene在6个月时的完全缓解率提高至62%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENGN":0.9},"content_text":"BRIEF-Detalimogene Demonstrates Improved Complete Response Rate Of 62% At 6 MonthsNov 11 (Reuters) - enGene Holdings Inc ENGN.O:DETALIMOGENE DEMONSTRATES IMPROVED COMPLETE RESPONSE RATE OF 62% AT 6 MONTHSENGENE HOLDINGS INC - 42% OF PATIENTS EXPERIENCED TREATMENT-RELATED ADVERSE EVENTSENGENE HOLDINGS INC - 1.6% OF PATIENTS HAD DOSE INTERRUPTIONS DUE TO ADVERSE EVENTSENGENE HOLDINGS INC: 0.8% OF PATIENTS EXPERIENCED DOSE DISCONTINUATIONS DUE TO TRAESSource text: ID:nBw7kBBjgaFurther company coverage: ENGN.O ((reuters.briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}